Conmed (NASDAQ: CNMD) reported Q2 EPS of $0.41, in-line with the analyst estimate of $0.41. Revenue for the quarter came in at $197.15 million versus the consensus estimate of $194.5 million.

GUIDANCE:

Conmed sees FY2017 EPS of $1.85-$1.95, raises revenue for FY 2017 to 2-3% from 1-6% prior.

For earnings history and earnings-related data on Conmed (CNMD) click here.